Unmasking silent atherosclerosis in type 2 diabetes: the emerging role of adipocyte fatty acid-binding protein
References
- Alvim RO, Dias FAL, Oliveira CM, Horimoto ARVR, Ulbrich AZ, Krieger JE, Pereira AC. Prevalence of peripheral artery disease and associated risk factors in a Brazilian rural population: The Baependi heart study. Int J Cardiovasc Sci 31, 405–413, 2018.
- Allam H, Tantawi H. Relationship between serum adipocyte fatty acid-binding protein and atherosclerosis in type 2 diabetes patients. Egypt J Hosp Med 83, 1484–1489, 2021.
- American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: Standards of Care in Diabetes–2024. Diabetes Care 47 (Suppl 1), S20–S42, 2024.
- Aminbakhsh A, Mancini GBJ. Carotid intima-media thickness measurements: What defines an abnormality? A systematic review. Clin Invest Med 22, 149–157, 1999.
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310, 2191–2194, 2013.
- Bagheri R, Qasim AN, Mehta NN, Terembula K, Kapoor S, Braunstein S, Schutta M, Iqbal N, Lehrke M, Reilly MP. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol 106, 1118–1123, 2010.
- Chow WS, Tso AW, Xu A, Yuen MM, Fong CH, Lam TH, Lo SV, Tse HF, Woo YC, Yeung CY, Cheung BMY, Lam KSL. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: A 12-year prospective study. J Am Heart Assoc 2, e004176, 2013.
- El-Sayed W, Eman S, Maram Mm, Elzoghby Dm, Safeya M. Circulating adipocyte fatty acid binding protein (AFABP): Predictor of metabolic syndrome in patients with type 2DM. Med J Cairo Univ 87, 4199–4206, 2019.
- Furuhashi M. Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb 26, 216–232, 2019.
- GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234, 2023.
- Jing F, Mao Y, Guo J, Zhang Z, Li Y, Ye Z, Ding Y, Wang J, Jin M, Chen K. The value of apolipoprotein B/apolipo-protein A1 ratio for metabolic syndrome diagnosis in a Chinese population: A cross-sectional study. Lipids Health Dis 13, 81, 2014.
- Lee CH, Lui DTW, Lam KSL. Adipocyte fatty acid-binding protein, cardiovascular diseases and mortality. Front Immunol 12, 589206, 2021.
- Mauvais-Jarvis F. Sex differences in metabolic homeostasis, diabetes, and obesity. Biol Sex Differ 6, 14, 2015.
- Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, Yoshifumi Ninomiya Y. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 211, 164–169, 2010.
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: A pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 404, 2077–2093, 2024.
- Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes. Prog Cardiovasc Dis 62, 306–314, 2019.
- Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB, Hotamisligil GS. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 103, 6970–6975, 2006.
- World Health Organization. Report of the fifth meeting of the WHO Technical Advisory Group on Diabetes: hybrid meeting, 7–8 June 2023. Geneva: World Health Organization; 2023. CIP data are available at http://apps.who.int/iris.
- Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NMS, Wong WK, Lam KSL. Adipocyte fatty acid–binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52, 405–413, 2006.
- Xiao Y, Xiao X, Xu A, Chen X, Tang W, Zhou Z. Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes. J Diabetes Complications 32, 1100–1104, 2018.
- Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective. Postgrad Med J 92, 63–69, 2016.
Language: English
Page range: 190 - 195
Published on: Aug 31, 2026
Published by: Slovak Academy of Sciences, Institute of Experimental Endocrinology
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Magui Abd Elmonem Shalash, Noha Said Kandil, Omnia Ezz Eldin Alsaadany, Aya Fathy Radwan, Reem Mahmoud Fathalla, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.